초록
본 연구는 살충제 amitraz의 피하투여 급성독성을 평가하기 위해 0, 2, 10 및 50 mg/kg용량으로 1회 피하투여한 후, 사망률과 일반증상, 체중, 혈액 및 혈청생화학 및 부검소견에 미치는 영향을 평가하였다. 시험결과, 비글 개에 있어서 amitraz의 단회 피하투여는 식욕부진과 침울, 구토, 유루, 운동성감소, 보행실조, 투여부위의 부종, 종괴 및 농양형성, 사지의 부전마비, 횡와위, 빈사, 사망, 체중감소, 투여부위의 근육출혈과 염증, 그리고 간과 신장의 충혈을 유발하는 것으로 나타났다. 반면, 투여 후 14일째에 생존동물의 혈액 및 혈청생화학치에서는 시험물질의 투여와 관련된 어떠한 변화도 인정되지 않았다. 결론적으로 본 시험조건하에서 비글 개에 대한 amitraz의 반수치사량은 22.3 mg/kg (95% 신뢰 한계: 산출되지 않음)이고, 무해용량(no-observed-adverse-effect level)은 2 mg/kg 이하로 사료된다.
The present study was carried out to investigate the potential acute toxicity of amitraz by a single subcutaneous dose in beagle dogs. The test chemical was administered subcutaneously to male beagle dogs at dose levels of 0, 2, 10, or 50 mg/kg. Mortalities, clinical findings, and body weight changes were monitored for the 14-day period following the administration. At the end of 14-day observation period, hematology, serum biochemistry, and gross postmortem examinations were examined. A single dog in the 50 mg/kg group was found dead on day 3 after treatment and the other two dogs in the group were sacrificed because of the severe clinical signs on day 7 after treatment. Treatment related clinical signs, including anorexia, edema, mass and abscess formation in the injection sites, depression, vomiting, lacrimation, decreased locomotor activity, ataxia, recumbency, paresis in the limbs, and/or moribundity were observed in all treatment groups in a dose-dependent manner. Decreased or suppressed body weight gain was also observed dose-dependently in all treated groups. In autopsy, dead animals in the 50 mg/kg group showed muscular hemorrhage and inflammation in the injection sites and congestion in the liver and kidney. The terminal sacrificed animals in the 10 mg/kg group also exhibited muscular hemorrhage and inflammation in the injection sites. Whereas, no treatment related effects on hematology and serum biochemistry were observed on day 14 after treatment at any dose tested. On the basis of the results, it was concluded that a single subcutaneous injection of amitraz to beagle dogs resulted in increased incidence of abnormal clinical signs and death, decreased body weight, and increased incidence of abnormal gross findings. In the experimental conditions, the $LD_{50}$value of amitraz was 22.3 mg/kg (95% confidence limit not specified) and the no-observed-adverse-effect level (NOAEL) was considered to be below 2 mg/kg for male dogs.
